Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 2017

View Archived Issues

Fusion Pharmaceuticals launches with series A financing to develop targeted radiotherapeutics

JCR plans to begin development of JR-162 to treat Pompe disease

FDA grants approval to initiate phase II study of saroglitazar in patients with PBC

Xynomic Pharmaceuticals acquires rights to abexinostat

Phase III study of fusidic acid achieves primary endpoint in patients with ABSSSI

EMA committee supports conditional marketing approval for Shire's Natpar

FDA grants fast track designation to Auris Medical's AM-111

EMA CHMP gives positive opinion on ZS-9 for hyperkalemia

Tafinlar plus Mekinist granted positive opinion in E.U. for BRAF-positive NSCLC

EMA committee recommends broadening approval of Darzalex

NDA resubmitted for latanoprostene bunod

TroVax treatment shows benefit in advanced colorectal cancer

MIODx and UCSF enter exclusive license agreement for two key immunotherapy technologies

EMA committee hands down positive opinion for Varuby

YKL-40 protein associated with neuronal damage in HIV-infected patients

Recordati signs licensing agreement with Meyer Hospital for retinopathy of prematurity treatment

Forty percent response rate seen with ImmunoPulse and pembrolizumab in resistant melanoma patients

Janssen patents free fatty acid receptor 1 agonists

Pfizer describes novel IRAK-4 inhibitors

NORD awards research grants to fund rare disease research

Roche describes new beta-secretase 1 inhibitors

Sunshine Lake Pharma synthesizes new 5-HT reuptake inhibitors and/or 5-HT1A receptor agonists

ViiV Healthcare patents HIV integrase inhibitors

The Broad Institute, Bayer Pharma identify novel EZH2 inhibitors

Seed extract DHP-1401 potentiates hippocampal synaptic transmission

EC approves Revlimid in new indication